Search

A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes

Therapeutic area :

Stringer F., DeJongh J., Scott G. and Danhof M., A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes. PAGE.(2013) [Link to publication]

Our expertise

Pain General modelling Cardiovascular Methods CNS Diabetes Lung Diseases Blood disorders Anti-infectives and immunology Endocrinology/Sexual health Safety pharmacology Biologicals Gastrointestinal Diseases Peripheral Nervous System Oncology Anesthesiology Paediatrics